BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: O’brien EC, Hellkamp AS, Neely ML, Swaminathan A, Bender S, Snyder LD, Culver DA, Conoscenti CS, Todd JL, Palmer SM, Leonard TB, Asi W, Baker A, Beegle S, Belperio JA, Condos R, Cordova F, Culver DA, de Andrade JA, Dilling D, Flaherty KR, Glassberg M, Gulati M, Guntupalli K, Gupta N, Hajari Case A, Hotchkin D, Huie T, Kaner R, Kim H, Kreider M, Lancaster L, Lasky J, Lederer D, Lee D, Liesching T, Lipchik R, Lobo J, Mageto Y, Menon P, Morrison L, Namen A, Oldham J, Raj R, Ramaswamy M, Russell T, Sachs P, Safdar Z, Sigal B, Silhan L, Strek M, Suliman S, Tabak J, Walia R, Whelan TP. Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis. Chest 2020;157:1188-98. [DOI: 10.1016/j.chest.2019.11.042] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Wuyts WA, Dahlqvist C, Slabbynck H, Schlesser M, Gusbin N, Compere C, Maddens S, Rizzo S, Kirchgaessler K, Bartley K, Bondue B. Quality of Life and Healthcare Resource Use in a Real-world Patient Population with Idiopathic Pulmonary Fibrosis: The PROOF Registry. Pulm Ther. [DOI: 10.1007/s41030-022-00187-8] [Reference Citation Analysis]
2 Guler SA, Clarenbach C, Brutsche M, Hostettler K, Brill AK, Schertel A, Geiser TK, Funke-Chambour M. Azithromycin for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis: A Randomized Controlled Cross-over Trial. Ann Am Thorac Soc 2021. [PMID: 34015241 DOI: 10.1513/AnnalsATS.202103-266OC] [Reference Citation Analysis]
3 Gao J, Kalafatis D, Carlson L, Pesonen IHA, Li CX, Wheelock Å, Magnusson JM, Sköld CM. Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry. Respir Res 2021;22:40. [PMID: 33546682 DOI: 10.1186/s12931-021-01634-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Cottin V, Bonniaud P, Cadranel J, Crestani B, Jouneau S, Marchand-Adam S, Nunes H, Wémeau-Stervinou L, Bergot E, Blanchard E, Borie R, Bourdin A, Chenivesse C, Clément A, Gomez E, Gondouin A, Hirschi S, Lebargy F, Marquette CH, Montani D, Prévot G, Quetant S, Reynaud-Gaubert M, Salaun M, Sanchez O, Trumbic B, Berkani K, Brillet PY, Campana M, Chalabreysse L, Chatté G, Debieuvre D, Ferretti G, Fourrier JM, Just N, Kambouchner M, Legrand B, Le Guillou F, Lhuillier JP, Mehdaoui A, Naccache JM, Paganon C, Rémy-Jardin M, Si-Mohamed S, Terrioux P; OrphaLung. [French practical guidelines for the diagnosis and management of IPF - 2021 update, full version]. Rev Mal Respir 2022:S0761-8425(22)00035-3. [PMID: 35752506 DOI: 10.1016/j.rmr.2022.01.014] [Reference Citation Analysis]
5 Pastre J, Barnett S, Ksovreli I, Taylor J, Brown AW, Shlobin OA, Ahmad K, Khangoora V, Aryal S, King CS, Nathan SD. Idiopathic pulmonary fibrosis patients with severe physiologic impairment: characteristics and outcomes. Respir Res 2021;22:5. [PMID: 33407450 DOI: 10.1186/s12931-020-01600-z] [Reference Citation Analysis]
6 Cox IA, de Graaff B, Ahmed H, Campbell J, Otahal P, Corte TJ, Glaspole I, Moodley Y, Goh N, Macansh S, Walters EH, Palmer AJ. The impact of idiopathic pulmonary fibrosis on health state utility values: evidence from Australia. Qual Life Res 2021;30:2615-32. [PMID: 33999322 DOI: 10.1007/s11136-021-02879-1] [Reference Citation Analysis]
7 Cox IA, Campbell J, de Graaff B, Otahal P, Corte TJ, Moodley Y, Hopkins P, Macansh S, Walters EH, Palmer AJ. Assessment of health-related quality of life in Australian patients with idiopathic pulmonary fibrosis: a comparison of the EQ-5D-5L and the AQoL-8D. Qual Life Res 2022. [PMID: 35927542 DOI: 10.1007/s11136-022-03205-z] [Reference Citation Analysis]
8 Cox IA, Borchers Arriagada N, de Graaff B, Corte TJ, Glaspole I, Lartey S, Walters EH, Palmer AJ. Health-related quality of life of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Eur Respir Rev 2020;29:200154. [PMID: 33153990 DOI: 10.1183/16000617.0154-2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
9 Nöhre M, Paslakis G, Albayrak Ö, Bauer-Hohmann M, Brederecke J, Eser-Valeri D, Tudorache I, de Zwaan M. Factor Analyses and Validity of the Transplant Evaluation Rating Scale (TERS) in a Large Sample of Lung Transplant Candidates. Front Psychiatry 2020;11:373. [PMID: 32425836 DOI: 10.3389/fpsyt.2020.00373] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Lancaster L, Bonella F, Inoue Y, Cottin V, Siddall J, Small M, Langley J. Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden. Respirology 2021. [PMID: 34611971 DOI: 10.1111/resp.14154] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]